CT
This biotechnology company develops enzyme inhibitors specifically targeting inflammation-related pathways to treat multiple sclerosis and other inflammation-based diseases. By screening and identifying novel inhibitors, the company provides healthcare professionals with effective therapeutic options for managing these conditions.
Updated 3 months ago
Funding
$750K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This biotechnology company develops enzyme inhibitors specifically targeting inflammation-related pathways to treat multiple sclerosis and other inflammation-based diseases. By screening and identifying novel inhibitors, the company provides healthcare professionals with effective therapeutic options for managing these conditions.